REPLIGEN CORP

Repligen Corporation announced its participation in the Jefferies Global Healthcare Conference in London, UK. CEO Olivier Loeillot is scheduled to participate in an analyst-led discussion on November 18th at 2:00 p.m. GMT. The company will provide a live webcast of the presentation on its Investor Relations website, which will also be available for replay.

Repligen reported a mixed second quarter for 2026, with total revenue increasing to $204.1 million from $182.4 million year-over-year. However, net income significantly decreased to $5.0 million from $14.9 million in the prior year's quarter, resulting in diluted EPS of $0.09, down from $0.26. The company completed the divestiture of Polymem S.A.S. for $3.6 million, incurring a net loss of $13.7 million, and continued its restructuring activities with charges of $4.2 million for the first six months of the year.

Repligen Corporation reported strong financial results for the second quarter ended June 30, 2026, with revenue reaching $204 million, marking a 12% reported and 13% organic increase year-over-year. Adjusted EPS rose significantly to $0.54 from $0.37 in the prior year period. The company also raised its full-year 2026 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS guidance to $2.03-$2.09, reflecting confidence in its performance. Additionally, Repligen announced a definitive agreement to acquire BioLife Solutions, aiming to strengthen its position in cell therapy.

Repligen Corporation announced a definitive agreement to acquire BioLife Solutions, a strategic move expected to enhance its cell therapy leadership and be accretive to revenue growth, margin, and adjusted EPS. Concurrently, the company reported strong second-quarter 2026 financial results, with revenue reaching $204 million, marking a 13% organic year-over-year increase, and adjusted operating income growing by 55%. Based on these strong results and improved outlook, Repligen raised its full-year 2026 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS guidance to $2.03-$2.09.

Repligen Corporation announced a definitive agreement to acquire BioLife Solutions for approximately $1.5 billion in total enterprise value. The transaction, comprising 64% Repligen common stock and 36% cash, is expected to be accretive to Repligen's top-line growth, adjusted margins, and adjusted EPS by at least $0.05 in year one and $0.25 in year two. The acquisition aims to strengthen Repligen's position in the high-growth cell therapy market. Both companies also reported preliminary Q2 2026 revenue growth, with Repligen at 12% reported (13% organic) and BioLife at 21% year-over-year to $28.5 million.

Repligen Corporation announced it will report its second quarter 2026 financial results on Tuesday, July 28, 2026. The company plans to issue a press release before market open and will host a conference call at 8:00 a.m. ET to discuss the results and business updates. A webcast of the call will also be available through the Investor Relations section of Repligen's website.

Repligen Corporation announced its participation in the William Blair 46th Annual Growth Stock Conference in Chicago, IL. Olivier Loeillot, President and Chief Executive Officer, will present a company overview on June 3rd at 10:40 a.m. CT. A live webcast of the presentation will be accessible via Repligen's Investor Relations website, with a replay available for a limited time.

Repligen Corporation announced the digital publication of its 2025 Corporate Sustainability Report, themed "Driving Sustainable Growth Together." The report details progress across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities, and Pathways to Success. It includes disclosures aligned with UN SDGs, GRI, SASB, and TCFD standards, reinforcing the company's commitment to transparency and continuous improvement in sustainability.

Repligen reported a rise in Q1 2026 total revenue to $194.26 million, up from $169.17 million in the prior year. Net income also increased to $8.33 million, or $0.15 per basic share, compared to $5.83 million, or $0.10 per basic share, in Q1 2025. The company completed the sale of Polymem S.A.S. for approximately $4.4 million, resulting in a $13.8 million loss on sale, and initiated restructuring activities to optimize its global manufacturing footprint.

Repligen Corporation reported a strong start to 2026, with first-quarter revenue increasing 15% to $194 million and adjusted EPS rising 23% to $0.48. The company also raised its full-year 2026 adjusted EPS guidance to $1.97-$2.05, reflecting confidence in its outlook. Strategic initiatives include a new OEM partnership in China, the launch of a Transformation Office focused on profitable growth, and the divestiture of the non-core Polymem filtration business.